Machine-learning metabolomics identifies DHEAS and citrate signatures in anti-MDA5 dermatomyositis
In a single-centre cohort of 183 patients with idiopathic inflammatory myopathy and 104 healthy controls, seven machine-learning classifiers and LASSO feature selection were used with plasma and PBMC metabolomics to distinguish anti-MDA5-positive dermatomyositis. DHEAS and citrate were selected across the integrated analyses; plasma assays showed lower levels in anti-MDA5-positive cases, with concordant patterns reported in a separate 33-patient/33-control validation cohort. Within cases, DHEAS correlated inversely with rapidly progressive interstitial lung disease and citrate with rash.
Technology: Seven machine-learning classifiers (including random forest and XGBoost) with LASSO feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In a single-centre cohort of 183 patients with idiopathic inflammatory myopathy and 104 healthy controls, seven machine-learning classifiers and LASSO feature selection were used with plasma and PBMC metabolomics to distinguish anti-MDA5-positive dermatomyositis.
- Still unknown: Single-centre study with a relatively small validation group (33 anti-MDA5-positive cases and 33 controls). The metabolite associations with RP-ILD and rash are observational and do not establish causality. Reported discrimination is exploratory and does not establish a clinical diagnostic test or patient benefit; no treatment response was studied. DHEAS and citrate are known metabolites; the paper-specific result is their measured profile and candidate biomarker association in this disease cohort.
- AI role: The models ranked discriminatory metabolites and selected features for disease classification; the team integrated these with pathway results to prioritize candidate biomarkers. DHEAS and citrate were then measured using ELISA and a biochemical assay, with patterns assessed in the validation cohort. Machine learning aided biomarker selection and classification; assays and clinical data supplied validation.
Evidence sources: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-025-03676-8
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.